Packy McCormick doesn't just predict the future of technology; he identifies a sudden, coordinated pivot by the world's most formidable operators toward the physical world. The most surprising claim here isn't that robots will get better, but that the era of purely digital disruption is ending, replaced by a "gigachad" industrial renaissance where the goal is to digitize matter itself. McCormick brings a rare synthesis of hard-nosed operational history and cutting-edge biotech to argue that we are entering a new American millennium defined by autonomy, manufacturing, and biological engineering.
The Return of the Physical Operator
McCormick anchors his optimism in the resurgence of Travis Kalanick, framing his return not as a comeback story, but as a strategic evolution. The author notes that Kalanick spent nearly eight years in "the most extreme version of stealth mode any modern founder has pulled off," building a $15 billion food infrastructure empire before revealing it. McCormick writes, "Travis. Kalanick. Is. Back." This blunt declaration sets the tone for a piece that values execution over hype. The core of the argument is that Kalanick's new venture, Atoms, represents a fundamental rejection of the current obsession with humanoid robots. Instead of building walking machines that mimic humans, Atoms is building "a wheelbase for robots" and acquiring autonomous mining tech from Pronto AI, a startup founded by Anthony Levandowski, the former Waymo founder whose own history with autonomous vehicles adds a layer of complex, high-stakes context to this new chapter.
McCormick highlights the pragmatism of this approach by quoting Kalanick's own assessment of recent robotic competitions: "The recent humanoid Olympics in Beijing highlighted many advances in humanoid development... I watched the half-marathon and couldn't help but think how much better it would be if they just had wheels." This observation is the piece's most effective reframing of the robotics landscape. It suggests that the industry is maturing beyond the novelty of bipedalism toward functional efficiency. McCormick argues that Kalanick's first attempt was to digitize the physical world with Uber, but Atoms is "the rest of it."
Uber was Kalanick's first attempt to digitize the physical world. Atoms seems to be the rest of it.
Critics might note that Kalanick's track record includes significant turbulence and investor ousting, which could cast doubt on the stability of this new venture. However, McCormick counters this by pointing to the sheer scale of the stealth operation, suggesting that the founder has learned from past volatility to build something more robust. The argument holds weight because it focuses on the underlying technology stack rather than the personality cult often associated with Kalanick.
The Industrial Rollup Playbook
The commentary shifts to Jeff Bezos, whose reported plan to raise a $100 billion fund for AI manufacturing signals a massive capital reallocation. McCormick describes this as "the gigachad version of the AI rollup playbook," targeting chipmaking, defense, and aerospace. The author connects this to a broader trend, noting that if you had predicted a few years ago that "Jeff Bezos, Travis Kalanick, and Elon Musk were going to be competing to industrialize America harder," you would have been dismissed. Now, the convergence of these three figures suggests a structural shift in the economy. McCormick writes, "Imagine going out to raise one of the largest funds in history... and that is less than 50% of your personal net worth." This hyperbole serves to underscore the sheer magnitude of the capital available for physical infrastructure.
The author links Bezos's "Project Prometheus" to the concept of "World Models," or AI that can understand and simulate the physical world. This connects the financial move to the technical capability, arguing that the bottleneck is no longer software, but the ability to manufacture and deploy hardware at scale. McCormick suggests this is a response to the bear market sentiment that "America couldn't build things anymore," turning that pessimism into a massive opportunity for those willing to invest in the supply chain.
Mining and Medicine: The Autonomy Frontier
McCormick extends the theme of autonomy beyond consumer tech into the gritty realities of mining and the delicate precision of medicine. In the mining sector, the author highlights Mariana Minerals' "Copper One" project, an autonomy-first mine and refinery in Utah. McCormick praises the company's plan to "Deploy PlantOS at scale to maximize copper recovery and reduce copper refining costs," arguing that the industry is structurally not winner-take-all, allowing multiple players to thrive if they can access high-grade deposits. This section reinforces the idea that the next wave of innovation is about efficiency in resource extraction, a critical need for the electrification of the global economy.
The argument then pivots to a breakthrough in cancer treatment from the University of California San Francisco. McCormick contrasts the current CAR-T therapy, which is expensive and labor-intensive, with a new "two-particle injection system" that reprograms T cells inside the body. The author writes, "Instead of the extract-engineer-expand-reinfuse pipeline, they designed a two-particle injection system that reprograms T cells inside the body." This shift from an external manufacturing process to an in-vivo solution is presented as a potential democratization of life-saving treatment. McCormick notes that in mice, the approach "cleared detectable leukemia in nearly all animals within two weeks," and that the engineered cells retained their "stemness" because they never left the body.
Just a quick shot, a follow-up, and back at it. Say it with us… get fucked, cancer.
A counterargument worth considering is the leap from mouse models to human trials, which has historically been a graveyard for promising cancer therapies. McCormick acknowledges this, stating, "As always, it's important to remember that mice are not people," but the optimism is grounded in the specific mechanism of the treatment, which avoids the random integration risks that can cause secondary cancers. The potential to turn a $400,000 last-resort therapy into a vaccine-like injection is a compelling narrative hook that justifies the author's enthusiasm.
The Neuroscience of Mindfulness
Finally, McCormick explores the intersection of technology and consciousness, citing a study on ultrasonic neuromodulation. The author connects this to the predictions of Shinzen Young, who argued that the "next Buddha" would be a collective of scientists and technologists making liberation accessible at scale. McCormick writes, "The ultrasound made the practice better and gave novices experienced meditator brains." The study found that targeted ultrasound could decouple the brain's default mode network from the central executive network in just two weeks, a state that usually takes hundreds of hours of meditation to achieve.
This section serves as a capstone to the author's broader thesis: that technology is not just optimizing our external world, but can also optimize our internal states. McCormick argues that without this kind of internal work, "the worst outcome would be for us to get all of the technological wonders we could have asked for and still be unhappy." The evidence presented suggests that we are on the verge of a new era where mental clarity is not just a spiritual pursuit, but a technological capability.
The next Buddha is a sangha.
Critics might argue that relying on technology to achieve states of mindfulness risks commodifying a deeply personal practice, potentially stripping it of its cultural and philosophical depth. However, McCormick's framing emphasizes the accessibility and democratization of the practice, suggesting that the goal is to help more people, not to replace the tradition.
Bottom Line
McCormick's strongest argument is the identification of a unified shift toward "physical AI," where the most capable operators are moving beyond software to solve hard problems in manufacturing, mining, and biology. The piece's biggest vulnerability is its optimism, which assumes that capital and technology will inevitably overcome regulatory and biological hurdles. Readers should watch for the successful translation of the UCSF cancer breakthrough into human trials, as that will be the true litmus test for this new era of in-vivo engineering.